title: Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in korean subjects with type 2 diabetes.
abstract: BACKGROUND
  The aims of this study are to investigate the glycemic efficacy and predictive parameters of vildagliptin therapy in Korean subjects with type 2 diabetes.
  
  
  METHODS
  In this retrospective study, we retrieved data for subjects who were on twice-daily 50 mg vildagliptin for at least 6 months, and classified the subjects into five treatment groups. In three of the groups, we added vildagliptin to their existing medication regimen; in the other two groups, we replaced one of their existing medications with vildagliptin. We then analyzed the changes in glucose parameters and clinical characteristics.
  
  
  RESULTS
  Ultimately, 327 subjects were analyzed in this study. Vildagliptin significantly improved hemoglobin A1c (HbA1c) levels over 6 months. The changes in HbA1c levels (ΔHbA1c) at month 6 were -2.24% (P=0.000), -0.77% (P=0.000), -0.80% (P=0.001), -0.61% (P=0.000), and -0.34% (P=0.025) for groups 1, 2, 3, 4, and 5, respectively, with significance. We also found significant decrements in fasting plasma glucose levels in groups 1, 2, 3, and 4 (P<0.05). Of the variables, initial HbA1c levels (P=0.032) and history of sulfonylurea use (P=0.026) were independently associated with responsiveness to vildagliptin treatment.
  
  
  CONCLUSIONS
  Vildagliptin was effective when it was used in subjects with poor glycemic control. It controlled fasting plasma glucose levels as well as sulfonylurea treatment in Korean type 2 diabetic subjects.
authors: Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
authors: Jin-Sun
authors: JS
authors: Chang
authors: Juyoung
authors: J
authors: Shin
authors: Hun-Sung
authors: HS
authors: Kim
authors: Kyung-Hee
authors: KH
authors: Kim
authors: Jeong-Ah
authors: JA
authors: Shin
authors: Kun-Ho
authors: KH
authors: Yoon
authors: Bong-Yun
authors: BY
authors: Cha
authors: Ho-Young
authors: HY
authors: Son
authors: Jae-Hyoung
authors: JH
authors: Cho
keywords: Diabetes mellitus; Dipeptidyl peptidase 4; Dipeptidyl peptidase 4 inhibitor; Vildagliptin